<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        128-116-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        REVCOX 200MG CAPSULE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CELECOXIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        21.8
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Novartis Pharmaceutical Manufacturing LLC" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Novartis Pharmaceutical Manufacturing LLC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Sandoz GmbH 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M01AH01 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;Revcox contains the active substance celecoxib which belongs to a group of medicines called nonsteroidal anti-inflammatory drugs (NSAID), and specifically a sub-group known as cyclooxygenase-2 (COX-2) inhibitors.. These work by lowering the amount of prostaglandins. Prostaglandins are substances made by your body. Some prostaglan- dins cause pain and inflammation, but others help protect the stomach lining. Revcox reduces prostaglandins that cause pain and inflammation and not the ones that protect the stomach.</p><p>Revcox is used in adults for pain relief and to alleviate swelling of tissue in the degenerative joint disease (osteoarthritis), inflammatory rheumatic joint disease (rheumatoid arthritis) and in certain types of inflammation of intervertebral joints (ankylosing spondylitis).</p><p>You should expect your medicine to start working within hours of taking the first dose, but you may not experience a full effect for several days.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Revcox, if you:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are allergic to celecoxib or any of the ingredients &nbsp;of this medicine (listed in section 6)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have had an <strong>allergic reaction </strong>to a group of medicines called &ldquo;sulfonamides&rdquo; (e.g. some antibiotics used to treat infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have currently stomach or duodenal ulcer or bleeding in the stomach or intestine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have had asthma , <strong>nose polyps, severe nose congestion,&nbsp; </strong>or an allergic reaction such as an itchy skin rash, swelling of the face, lips, tongue or throat, breathing difficulties, or wheezing as a result of taking acetysalicy clic acid &nbsp;or any other anti-inflammatory and pain relieving medicine (NSAID, e.g. ibuprofen, including cyclooxygenase-2 (COX-2) inhibitors)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have severe liver disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have severe kidney disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are pregnant or are in your fertile period (if it is <strong>possible </strong>for you to <strong>become pregnant </strong>during ongoing treatment you should discuss methods of contraception with your doctor )</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are breast-feeding</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have an inflammatory disease of the intestines, such as ulcerative colitis or Crohn&rsquo;s disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have heart <strong>failure</strong>, established ischaemic <strong>heart disease </strong>or <strong>cerebrovascular disease</strong>, e.g. you have been diagnosed with a heart attack, stroke, or transient ischaemic attack (temporary reduction of blood flow to the brain; also known as &ldquo;mini-stroke&rdquo;), angina or blockages of blood vessels to the heart or brain&nbsp;&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have or have had problems with your blood circulation (peripheral arterial disease) or if you have had surgery on the arteries of your legs.</p><p>&nbsp;</p><p>If you think any of the above conditions applies to youconsult your doctor or pharmacists.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Revcox if you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have heart, liver or kidney problems your doctor may want to keep a regular check on you</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are dehydrated due to vomiting, diarrhoea or the use of diuretics (used to treat excess fluid in the body)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have oedema (fluid retention, such as swollen ankles and feet)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have previously&nbsp; had a stomach or duodenal (intestinal) ulcer or bleeding in the stomach or intestines</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feel ill due to an infection or think you have an infection, as Revcox may mask a fever &nbsp;or other signs of an infection and inflammation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; smoke, have diabetes, raised blood pressure or raised levels of cholesterol in your blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have had a serious allergic reaction or a serious skin reaction to any medicines</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are over 65 years of age: your doctor will want to monitor you regularly.</p><p>As with other NSAIDs (e.g. ibuprofen or diclofenac) this medicine may lead to an increase in blood pressure, and so your doctor may ask to monitor your blood pressure on a regular basis.</p><p>Some cases of severe liver reactions, including severe liver inflammation, liver damage, liver failure (some with fatal outcome or requiring liver transplant), have been reported with celecoxib. Of the cases that reported time to onset, most severe liver reactions occurred within one month of start of treatment.</p><p>Revcox may make it more difficult to become pregnant. You should inform your doctor if you are planning to become pregnant or if you have problems to become pregnant (see section on Pregnancy and breast-feeding).</p><p><strong>Children and adolescents</strong></p><p>&nbsp;</p><p>Revcox is for adults only. It is not for use in children.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Other medicines and Revcox</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>In particular, it is very important to tell your doctor if you are taking any of the following medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to reduce blood clotting, e.g. <strong>warfarin/coumarin like anticoagulants </strong>or novel oral anti-clotting medicines such as <strong>apixaban, dabigatran </strong>or <strong>rivaroxaban</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:line
 id="_x0000_s1026" style='position:absolute;left:0;text-align:left;z-index:251655168;
 mso-position-horizontal-relative:page' from="35.75pt,13.85pt" to="35.75pt,27.3pt"
 strokeweight=".72pt">
 <w:wrap anchorx="page"/>
</v:line><![endif]--><img width="2" height="20" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/2/msohtmlclip1/01/clip_image001.gif" />medicines called <strong>corticosteroids </strong>(e.g. prednisone)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><u>antiplatelet therapies</u></strong><u>, e.g. acetylsalicylic acid (see below)</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>acetylsalicylic acid </strong>(even at low dose for heart protective purposes) or <strong>other nonsteroidal anti-inflammatory medicines (NSAIDs), </strong>e.g. ibuprofen or diclofenac. You should avoid taking celecoxib and non-acetysalicyclic acid anti-inflammatory medicines concomitantly. Revcox can be taken with low dose acetylsalicylic acid (75 mg or less daily). Ask your doctor for advice before taking both medicines together.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ACE inhibitors</strong>, medicines for treatment of heart problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>angiotensin II receptor antagonists</strong>, medicines for treatment of heart problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>beta blockers</strong>, medicines used for high blood pressure and heart failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>barbiturates</strong>, medicines for treating epilepsy/fits or insomnia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>carbamazepine</strong>, a medicine for treating epilepsy/fits or some types of pain or depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>citalopram, imipramine</strong>, medicines for treating depression, or <strong>lithium </strong>(used to treat manic phase in bipolar disorder (type of depression))</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines to treat <strong>depression </strong>(tricyclics and SSRIs-selective serotonin reuptake inhibitors)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ciclosporin </strong>or <strong>tacrolimus</strong>, medicines used to prevent rejection in transplant patients</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>dextromethorphan</strong>, a medicine used in some cough mixtures</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>diazepam</strong>, a medicine to treat insomnia or anxiety</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>diuretics</strong>, medicines to treat high blood pressure, heart failure or excess fluid in the body</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>fluconazole</strong>, a medicine used to treat fungal infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>methotrexate</strong>, a medicine for treatment of rheumatoid arthritis, psoriasis or leukemia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>rifampicin</strong>, a medicine for treatment of bacterial infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for treating <strong>psychoses </strong>and <strong>schizophrenia </strong>(neuroleptics)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for treating <strong>sleep disorders, high blood pressure </strong>or an <strong>irregular heart beat </strong>(anti- arrhythmics)</p><p>&nbsp;</p><p>Ask your doctor if you are not sure which of these medicines you are taking.</p><p>&nbsp;</p><p><strong>Revcox with alcohol</strong></p><p>The consumption of alcohol is not recommended when taking Revcox since it may increase the risk of gastrointestinal problems.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You <strong>must not use </strong>Revcox if you are <strong>pregnant </strong>or <strong>can become pregnant </strong>(i.e. women of child bearing potential who are not using adequate contraception) during ongoing treatment.</p><p>If you <strong>become pregnant </strong>while taking this medicine, <strong>stop taking it immediately </strong>and tell your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not take </strong>this medicine if you are <strong>breast-feeding</strong>.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NSAIDs, including Revcox , may make it more difficult to become pregnant. You should tell your doctor if you are planning to become pregnant or if you have problems becoming pregnant.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>You may feel dizzy or drowsy after taking Revcox . If this happens, do not drive or operate machinery until these effects wear off.</p><p>&nbsp;</p><p><strong>Revcox contains lactose (a type of sugar)</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>&nbsp;</p><p><strong>Revcox contains sodium</strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has&nbsp; told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;As the risk of side effects associated with heart problems may increase with dose and duration of use, it is important that you use the lowest dose that controls your pain and you should not take this medicine for longer than necessary to control symptoms.</p><p>Contact your doctor within two weeks of starting treatment if you do not experience any benefit.</p><p>The recommended dose is:</p><p><strong>For degenerative joint disease (Osteroarthritis)</strong></p><p>The recommended dose is 200 mg &nbsp;each day, increased by your doctor to a maximum of 400 mg, if needed.</p><p>The dose is usually:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; one 200 mg capsule once a day; or</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; one 100 mg capsule twice a day.</p><p><strong>For inflammatory rheumatic joint disease (Rheumatoid arthritis)</strong></p><p>the recommended dose is 200 mg each day, increased by your doctor to a maximum of 400 mg, if needed.</p><p>The dose is usually:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; one 100 mg capsule twice a day.</p><p>&nbsp;</p><p><strong>For certain types of inflammation of intervertebral joints&nbsp; (Ankylosing spondylitis)</strong></p><p>the recommended dose is 200 mg each day, increased by your doctor to a maximum of 400 mg, if needed. The dose is usually:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; one 200 mg capsule once a day; or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; one 100 mg capsule twice a day.</p><p><strong>&nbsp;</strong></p><p><strong>Do not take more than 400 mg per day </strong>in all therapeutic uses.</p><p>&nbsp;</p><p><strong>The Elderly </strong></p><p>If you are over 65 years of age and especially if you weigh less than 50 kg, your doctor may want to monitor you more closely.</p><p>Kidney or liver problems</p><p><strong>&nbsp;</strong></p><p>Make sure your doctor knows if you have liver or kidney problems as you may need a lower dose.</p><p><strong>Method&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; use Revcox is</strong></p><p>for oral use. Take your capsule(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swallow them whole with a glass of water</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; preferably at the same time each day</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with or without food.</p><p>If you have difficulty swallowing capsules: The entire capsule contents can be sprinkled onto a level teaspoon of semi-solid food (such as cool or room temperature applesauce, rice gruel, yogurt or mashed banana) and swallowed immediately with a glass of water.</p><p>To open the capsule, hold upright to contain the granules at the bottom then gently squeeze the top and twist to remove, taking care not to spill the contents. <strong>Do not chew or crush the pellets.</strong></p><p><strong>If you take more Revcox than you should</strong></p><p>If you take too many capsules, contact your nearest hospital casualty department or tell your doctor immediately. Take your medicine with you to show the doctor what you have taken.</p><p><strong>If you forget to take Revcox </strong></p><p>It is important to take your medicine every day. However, if you forget to take one or more doses, take it as soon as you remember and then continue with your normal schedule. Do not take a double dose to make up for a forgotten dose</p><p><strong>&nbsp;If you stop taking Revcox</strong></p><p>Always consult your doctor, before you stop taking this medicine. Even if you feel well, your doctor may decide that it is necessary to continue taking this medicine.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>The side effects listed below were observed in arthritis patients who took celecoxib. Side effects marked with an asterisk (*) are listed below at the higher frequencies that occurred in patients who took celecoxib to prevent colon polyps. Patients in these studies took celecoxib at high doses and for a long duration.</strong></p><p><strong>If any of the following happen, stop taking Revcox and tell your doctor immediately:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an allergic reaction such as skin rash, swelling of the face, wheezing or difficulty breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart problems such as pain in the chest</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe stomach pain or any sign of bleeding in the stomach or intestines, such as passing black or bloodstained stools, or vomiting blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a skin reaction such as rash, blistering or peeling of the skin</p><p>liver failure (symptoms may include nausea (feeling sick), diarrhoea, jaundice (your skin or the whites of your eyes look yellow)).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Possible side effects:</p><p><strong>&nbsp;</strong></p><p><strong>Very common</strong>, may affect more than 1 in 10 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure, including worsening of existing high blood pressure*</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>Common</strong> , may affect up to 1 in 10 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the sinuses (sinusitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upper respiratory tract infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urinary infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; worsening of existing allergies</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty sleeping, dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle stiffness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart attack*</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breathing difficulty*</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sore throat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; runny or stuffy nose, sneezing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach &nbsp;ache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indigestion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; wind</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea (feeling sick)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting *</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty swallowing*</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash, itching of the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; painful joints</p><p>&nbsp;fluid build up with swollen ankles, legs and/or hands&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flu-like symptoms</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; accidental injury</p><p><strong>Uncommon</strong> &nbsp;may affect up to 1 in 100 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduction in red blood cells which can make the skin pale and cause weakness or breathlessness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high level of blood potassium which can cause muscle weakness, twitching or abnormal heart rhythm</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anxiety, depression, tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stroke*</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision, eye inflammation (conjunctivitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tingling or numbness (paraesthesia) ), sleepiness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ringing in the ears, difficulty hearing*</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; myocardial infarction</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; faster heart beat or feeling your heartbeat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty breathing difficulty breathing (bronchospasm)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation, burping, stomach inflammation, worsening of inflammation of the stomach or intestine&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mouth pain and sores&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; raised itchy rash (hives)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changed liver function, increased levels of liver enzymes in the blood such as SGOT, SGPT&bull;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin discolouration (bruising)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; leg cramps</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in kidney-related blood tests: increased levels of creatinine and blood urea nitrogen</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; face swelling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain (generalised pain not related to the heart)</p><p><strong>Rare</strong> &nbsp;, may affect up to 1 in 1,000 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced number of white blood cells , which help protect the body from infection (leucopenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced number of blood platelets &nbsp;, which increases risk of bleeding or bruising</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; confusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hallucinations</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty in controlling movements (ataxia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in the way things taste&bull;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding in the eye</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irregular heartbeat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clot in the blood vessels in the lungs. Symptoms may include sudden breathlessness, sharp pains when you breathe or collapse.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acute reaction that may lead to lung inflammation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flushing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding of the stomach or intestines (can lead to bloody stools or vomiting), inflammation of the intestine or colon</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ulcers (bleeding) in the gullet, stomach, intestines or rupture of the intestine (can cause stomach ache, fever, nausea, vomiting, intestinal blockage) &bull;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dark or black stools</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the gullet with &nbsp;difficulty in swallowing (oesophagitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of pancreas, which causes severe pain in the abdomen and back</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe liver inflammation (hepatitis). Symptoms may include nausea (feeling sick), diarrhoea, jaundice (yellow discolouration of the skin or eyes), dark urine, pale stools, bleeding easily, itching or chills</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face, lips, mouth, tongue or throat, or difficulty swallowing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of hair</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased sensitivity to light</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acute kidney failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood levels of sodium which can cause tiredness, confusion, muscle twitching, fits and coma</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; menstrual disturbances</p><p><strong>Very</strong> <strong>&nbsp;rare</strong>, may affect up to 1 in 10,000 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a reduction in the number of red and white blood cells and platelets (may cause tiredness, easy bruising, frequent nose bleeds and increased risk of infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious allergic reactions including possibly fatal anaphylactic shock</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding within the brain including fatal cases</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the membrane around the brain and spinal cord not caused by infection (aseptic meningitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fits or worsening of epilepsy (possible more frequent and/or severe seizures)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of sense of taste</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of sense of smell</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blockage of an artery or vein in the eye leading to partial or complete loss of vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of a blood vessel which can cause fever, aches and purple blotches on the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver failure,liver damage, severe inflammation of the liver (fulminant hepatitis) (sometimes fatal or requiring liver transplant). Symptoms may include nausea (feeling sick), diarrhoea, jaundice (yellow discolouration of the skin or eyes), dark urine, pale stools, bleeding easily, itching or chills. Of the cases that reported time to onset, most severe liver reactions occurred within one month of start of treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver problems such as cholestasis and cholestatic hepatitis, which may be accompanied by symptoms such as discoloured stools, nausea and yellowing of the skin or eyes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious skin conditions such as Stevens-Johnson syndrome, exfoliative dermatitis , toxic epidermal necrolysis (can cause rash, blistering or peeling of the skin) and acute generalised exanthematous pustulosis (symptoms include the skin becoming red with swollen areas covered in numerous small pustules)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a delayed allergic reaction with possible symptoms such as rash, swelling of the face, fever, swollen glands and abnormal test results, concerning e.g. the liver or blood cells (eosinophilia, a type of raised white blood cell count). This reaction is called drug rash with eosinophilia and systemic symptoms (DRESS) or hypersensitivity syndrome.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle inflammation with pain and weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the kidneys and other kidney problems (such as nephrotic syndrome and minimal change disease, which may be accompanied by symptoms such as water retention (oedema), foamy urine, fatigue and loss of appetite)</p><p><strong>Frequency not known </strong>(frequency cannot be estimated from the available data)</p><p>decreased fertility in females, which is usually reversible after you stop taking this medicine</p><p>Furthermore, the following previously unknown side effects occurred in polyp prevention studies, where patients were taking 400 mg celecoxib daily:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common (may affect up to 1 in 10 people): chest pain (angina pectoris), irritable bowel syndrome (can include stomach ache, diarrhoea, indigestion, wind), kidney stones (which may lead to stomach or back pain, blood in urine), blood creatinine increased, benign prostatic hyperplasia with difficulty passing urine, weight increased.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncommon (may affect up to 1 in 100 people): stomach infection, which can cause irritation and ulcers of the stomach and intestines (Helicobacter infection), shingles, superficial infection of the skin (erysipelas), lung infection (bronchopneumonia - chest infection [possible cough, fever, difficulty breathing]), inner ear infection, gum infection, fatty lumps in skin or elsewhere (lipoma), floaters in the eye causing blurred or impaired vision, conjunctival bleeding, deep vein thrombosis (blood clot usually in the leg, which may cause pain, swelling or redness of the calf or breathing problems), voice disorder (difficulty speaking), bleeding from piles (haemorrhoids), frequent bowel movements, mouth sores, allergic dermatitis, ganglion cyst, a harmless swellings on or around joints and tendons in the hand or foot, excessive urination at night, abnormal or very heavy bleeding from the vagina, breast pain, lower limb fracture, blood sodium increased.</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects&nbsp; not listed in this leaflet. You can also report side effects directly via [the national reporting system listed in Appendix V of the QRD template; to be completed nationally]. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine&nbsp; out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;Store below 25&deg;C.Do not throw away any medicine through wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer need. This measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Revcox 100 mg capsules, hard: The active substance is celecoxib. Each hard&nbsp; capsule contains 100 mg celecoxib.</p><p>Revcox 200 mg capsules, hard: The active substance is celecoxib. Each hard&nbsp; capsule contains 200 mg celecoxib.</p><p>The other ingredients are:</p><p>Contents of capsule Revcox 100 mg and 200 mg capsules, hard: Carrageenan (E407), sodium laurilsulphate, lactose monohydrate, microcrystalline cellulose (E460), magnesium stearate (E470b), silica colloidal anhydrous (E551), talc (E553b).</p><p>Capsule shell Revcox 100 mg capsules, hard: Gelatin (E441), titanium dioxide (E171), indigo carmine (E132).</p><p>Capsule shell Revcox 200 mg capsules, hard:</p><p>Gelatin (E441), titanium dioxide (E171), iron oxide, red (E172), iron oxide, yellow (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Revcox 100 mg capsules, hard:
Capsules (length 17.7 – 18.3 mm) have white body and blue cap, containing white to slightly yellowish pellets.
Revcox 200 mg capsules, hard:
Capsules (length 19.1 – 19.7 mm) have white body and orange cap, containing white to slightly yellowish pellets.
Revcox hard caspules are packed in PVC/TE/PVDC/Alu foil blisters. Box contains: 10, 20, 30, 50, 60, 90 or 100 hard capsules.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing&nbsp; Authorization Holder</strong></p><p>Sandoz GmbH</p><p>Biochemiestrasse 10</p><p>Kundl, Austria</p><p><strong>Manufacturer</strong></p><p>Lek Pharmaceuticals d.d.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                April 2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي عقار ريفكوكس على المادة الفعَّالة سيليكوكسيب التي تنتمي إلى مجموعة من الأدوية تُسمى مضادات الالتهاب غير الستيرويدية، وتحديدًا المجموعة الفرعية التي تُعرَف باسم مثبطات إنزيم الأكسدة الحلقية- 2. تعمل هذه الأدوية عن طريق خفض كمية البروستاجلاندينات. البروستاجلاندينات هي مواد يصنعها جسمك. تُسبب بعض البروستاجلاندينات الألم والالتهاب، ولكن البعض الآخر يُساعِد في حماية بطانة المعدة. يقلل عقار ريفكوكس من البروستاجلاندينات التي تُسبب الألم والالتهاب لا التي تحمي المعدة.</p><p dir="RTL">يُستَخدَم عقار ريفكوكس في البالغين لتسكين الألم وتخفيف تورُّم النسيج في حالة الدَّاء المفصلي التنكسي (التهاب المفاصل) ومرض التهاب المفاصل الروماتيزمي (التهاب المفاصل الروماتويدي) وفي بعض أنواع التهاب المفاصل بين الفقرات (التهاب الفقار اللاصق).</p><p>عليك توقع بدء ظهور فعَّالية الدَّواء الخاص بك في غضون ساعات من تناوُل الجرعة الأولى، ولكن قد لا تشعر بتأثير كامل لعدة أيام.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول عقار ريفكوكس في الحالات التَّالية:</strong></p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى. على وجه الخصوص، من المهم للغاية إخبار طبيبك إذا كنت تتناول أي من الأدوية التَّالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية للحد من تجلط الدَّم،&nbsp; مثل <strong>الوارفارين/ الكومارين</strong> <strong>مثل الأدوية المضادة للتجلُّط</strong> أو الأدوية الفموية الجديدة المضادة للتجلُّط مثل: <strong>أبيكسابان أو دابيجاتران أو ريفاروكسابان</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تُسمى <strong>الكورتيكوستيرويدات</strong> (على سبيل المثال: بريدنيزون)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة للصفيحات، على سبيل المثال حمض أسيتيل الساليسيليك (انظر أدناه).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>حمض أسيتيل الساليسيليك</strong> (حتى عند استخدام الجرعة المنخفضة لأغراض وقاية القلب) أو <strong>غيره من</strong> <strong>مضادات الالتهاب غير الستيرويدية،</strong> على سبيل المثال: إيبوبروفين أو ديكلوفيناك. يجب عليك تجنُّب تناوُل سيليكوكسيب مع الأدوية المضادة للالتهاب التي لا تحتوي على حمض أسيتيل الساليسيليك بالتَّزامن. يُمكِن تناوُل عقار ريفكوكس مع جرعة منخفضة من حمض أسيتيل الساليسيليك (75 مجم أو أقل يوميًّا). يُرجى استشارة طبيبك قبل تناول كلا الدَّواءين معًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مُثبطات إنزيم تحويل الأنجيوتنسين</strong>، أدوية لعلاج مشاكل القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مناهضات مستقبلات أنجيوتنسين-2،</strong> أدوية لعلاج مشاكل القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>حاصرات بيتا،</strong> أدوية تُستَخدَم لعلاج ارتفاع ضغط الدَّم وفشل القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الباربيتورات</strong>، أدوية لعلاج الصرع/ النوبات التشنُّجية أو الأرَق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>كَرْبامازِيبين</strong>، دواء لعلاج الصَّرَع/ النوبات التشنُّجية أو بعض أنواع الألم أو الاكتئاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>سيتالوبرام</strong>، <strong>إيميبرامين</strong>، أدوية لعلاج الاكتئاب، أو الليثيوم (يُستَخدَم لعلاج مرحلة الهوس في حالات الاضْطِّراب ثنائي القطب (أحد أنواع الاكتئاب))</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى لعلاج <strong>الاكتئاب</strong> (مضادات الاكتئاب ثلاثية الحلقات ومثبطات إعادة امتصاص السيروتونين الانتقائية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>سيكلوسبورين</strong> أو <strong>تاكروليموس</strong>، أدوية تُستَخدَم لمنع رفض أجسام المرضى للعضو المزروع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ديكستروميثورفان</strong>، دواء يُستَخدَم في بعض خلائط السعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>دَيازِيبام</strong>، دواء لعلاج الأرق أو القلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مُدِرات البول</strong>، أدوية لعلاج ارتفاع ضغط الدَّم أو فشل القلب أو زيادة السوائل في الجسم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>فلوكونازول</strong>، دواء يُستَخدَم لعلاج العدوى الفطرية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ميثوتريكسات</strong>، دواء لعلاج التهاب المفاصل الروماتويدي أو الصدفية أو سرطان الدَّم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ريفامبيسين</strong>، دواء لعلاج العدوى البكتيرية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج حالات <strong>الذهان</strong> <strong>والفُصَام</strong> (مضادات الذهان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج<strong> اضطرابات النوم</strong> أو <strong>ارتفاع ضغط الدَّم</strong> أو عدم انتظام ضربات القلب<strong> </strong>(الأدوية المضادة لاضطرابات النظم القلبي)</p><p dir="RTL">اسأل طبيبك إذا لم تكن متأكدًا بشأن ما تتناوله من هذه الأدوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>عقار ريفكوكس مع الكحوليات</strong></p><p dir="RTL"><strong>&nbsp;</strong>يُوصى بعدم تناوُل الكحوليات عند تناول عقار ريفكوكس لأنه قد يزيد من خطر الإصابة بمشاكل الجهاز الهضمي.</p><p dir="RTL"><strong>الحمل والرَّضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">&nbsp;إذا كنتِ حاملًا أو مرضعًا، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين لذلك، فاستشيري طبيبكِ أو الصيدلي الخاص بكِ قبل تناوُل هذا الدَّواء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب <strong>ألا تستخدمي</strong> عقار ريفكوكس إذا كنتِ حاملًا أو قد تُصبحين حاملًا<strong> </strong>(أي، السيدات ممن لديهن القدرة على الحمل اللاتي لا يستخدمن وسائل مناسبة لمنع الحَمْل) أثناء العلاج المستمر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا <strong>أصبحتِ حاملًا</strong> أثناء تناوُل هذا الدَّواء، <strong>فتوقفي عن تناوله فورًا</strong> وأخبري طبيبكِ.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>يجب ألا تتناولي</strong> هذا الدَّواء إذا كنتِ <strong>مرضعًا</strong>.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مضادات الالتهاب غير الستيرويدية</strong>، وتشمل ريفكوكس، قد يجعل من الصعوبة الحمل. يجيب عليك إخبار طبيبك في حال خططت للحمل أو واجهتِ مشاكل في أن تصبحي حاملاً.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p>&nbsp;قد تشعر بدوخة أو نُعاس بعد تناوُل عقار ريفكوكس. إذا حدث ذلك، فتجنَّب قيادة المركبات أو تشغيل الآلات حتى تزول هذه الآثار.</p><p>&nbsp;يحتوي عقار ريفكوكس على اللاكتوز (أحد أنواع السكريات)</p><p dir="RTL">إذا كان طبيبك قد أخبرك بأنك لا تتحمل بعض أنواع السكريات، فاتصل به قبل تناول هذا الدَّواء.</p><p>يحتوي عقار ريفكوكس على الصوديوم</p><p dir="RTL">يحتوي هذا الدَّواء على أقل من 1 مللي مول من الصوديوم (23 مجم) بكل كبسولة، مما يعني أنه &quot;خالٍ من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائمًا هذا الدَّواء بالضبط كما أخبرك طبيبك أو الصيدلي الخاص بك. راجع طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية الاستخدام.</p><p dir="RTL">&nbsp;نظرًا لأن خطر الإصابة بالآثار الجانبية المصحوبة بمشاكل قلبية قد يزداد مع الجرعة ومدة الاستخدام، فمن المهم استخدام أدنى جُرعة تسيطر على الألم لديك، ويجب عدم تناول هذا الدَّواء لوقت أطول من اللازم للسيطرة على الأعراض.اتصل بطبيبك في غضون أسبوعين من بدء العلاج إذا لم تشعر بأيِّ فائدة له.</p><p>الجُرعة المُوصى بها هي:</p><p dir="RTL"><strong>لعلاج داء المفاصل التنكسي (التهاب المفاصل)</strong></p><p dir="RTL">يُوصى بجرعة قدرها 200 مجم كل يوم، على أن يقوم طبيبك بزيادتها إلى 400 مجم بحد أقصى، إذا لزم الأمر.</p><p dir="RTL">تكون الجرعة عادة كالتَّالي:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كبسولة واحدة 200 مجم مرة واحدة يوميًّا؛ أو</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كبسولة واحدة 100 مجم مرتين يوميًّا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>لعلاج مرض التهاب المفاصل الروماتيزمي (التهاب المفاصل الروماتويدي)</strong></p><p dir="RTL">يُوصى بجرعة قدرها 200 مجم كل يوم، على أن يقوم طبيبك بزيادتها إلى 400 مجم كحد أقصى، إذا لزم الأمر.</p><p dir="RTL">تكون الجرعة عادة كالتَّالي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كبسولة واحدة 100 مجم مرتين يوميًّا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لعلاج بعض أنواع التهاب المفاصل بين الفقرات (التهاب الفقار اللاصق)</strong></p><p dir="RTL">يُوصى بجرعة قدرها 200 مجم كل يوم، على أن يقوم طبيبك بزيادتها إلى 400 مجم كحد أقصى، إذا لزم الأمر. تكون الجرعة عادة كالتَّالي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كبسولة واحدة 200 مجم مرة واحدة يوميًّا؛ أو</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كبسولة واحدة 100 مجم مرتين يوميًّا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>لا تتناول أكثر من 400 مجم في اليوم</strong> في جميع الاستخدامات العلاجية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كبار السن </strong></p><p dir="RTL">إذا كان عمرك يزيد على 65 عامًا ولا سيَّما إذا كان وزنك أقل من 50 كجم، فقد يرغب طبيبك في مراقبة حالتك بشكل أكثر دقة.</p><p>مشاكل الكُلى أو الكبد</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">تأكَّد من علم طبيبك إذا كنت تعاني من مشاكل في الكبد أو الكُلى أم لا؛ إذ قد تحتاج إلى جرعة أقل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة الاستخدام عقار ريفكوكس</strong></p><p dir="RTL">مُعد للاستخدام عن طريق الفم. تناوَل كبسولتك (كبسولاتك) على النحو التَّالي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع الكبسولة (الكبسولات) كاملة مع كوب من الماء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُفضل في نفس الوقت من كل يوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنك تناولها مع الطعام أو بدونه.</p><p dir="RTL">إذا كنت تواجه صعوبة في ابتلاع الكبسولات: يُمكِن نثر محتويات الكبسولة بالكامل على ملعقة صغيرة تحتوي على طعام شبه صلب (مثل: صوص التفاح البارد أو في درجة حرارة الغرفة أو عصيدة الأرز أو الزبادي أو الموز المهروس) وابتلعها فورًا مع كوب من الماء.</p><p dir="RTL">لفتح الكبسولة، أمسكها بوضعية قائمة لتكون الحبيبات بالجزء السفلي، ثم اضغط برفق على الجزء العلوي ولفه لنزعه، مع الحرص على عدم سقوط المحتويات. <strong>لا تقم بمضغ أو طحن الكريات.</strong></p><p dir="RTL"><strong>إذا تناولت كمية أكثر مما يجب من عقار ريفكوكس</strong></p><p dir="RTL">إذا تناولت كمية أكثر مما يجب من الكبسولات، فاتصل بأقرب مستشفى لك بها قسم طوارئ أو أخبر طبيبك فورًا. خذ معك دواءك لتُظهر للطبيب ما الذي تناولته.</p><p dir="RTL"><strong>إذا أغفلت تناوُل عقار ريفكوكس </strong></p><p dir="RTL">من المُهِم تناوُل دوائك كل يوم. مع ذلك، إذا أغفلت تناوُل جرعة أو أكثر، فتناولها بمجرد تذكرك لها وبعد ذلك استمر في تناول الجرعات بحسب جدولك المعتاد. لا تتناول جرعة مضاعفة لتعويض جرعة أغفلتها.</p><p dir="RTL"><strong>&nbsp;إذا توقفت عن تناول ريفكوكس</strong></p><p dir="RTL">استشر طبيبك دائمًا قبل أن تتوقف عن تناوُل هذا الدَّواء. حتى إذا شعرت بأنك على ما يُرام، قد يقرر طبيبك أنه من الضَّروري مواصلة تناوُل هذا الدَّواء.</p><p dir="RTL">&nbsp;إذا كانت لديك أية أسئلة إضافية حول استخدام هذا المنتج، فاستشر طبيبك أو الصيدلي الخاص بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p>&nbsp;قد تشعر بدوخة أو نُعاس بعد تناوُل عقار ريفكوكس. إذا حدث ذلك، فتجنَّب قيادة المركبات أو تشغيل الآلات حتى تزول هذه الآثار.</p><p>&nbsp;يحتوي عقار ريفكوكس على اللاكتوز (أحد أنواع السكريات)</p><p dir="RTL">إذا كان طبيبك قد أخبرك بأنك لا تتحمل بعض أنواع السكريات، فاتصل به قبل تناول هذا الدَّواء.</p><p><strong>يحتوي عقار ريفكوكس على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدَّواء على أقل من 1 مللي مول من الصوديوم (23 مجم) بكل كبسولة، مما يعني أنه &quot;خالٍ من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائمًا هذا الدَّواء بالضبط كما أخبرك طبيبك أو الصيدلي الخاص بك. راجع طبيبك أو الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية الاستخدام.</p><p dir="RTL">&nbsp;نظرًا لأن خطر الإصابة بالآثار الجانبية المصحوبة بمشاكل قلبية قد يزداد مع الجرعة ومدة الاستخدام، فمن المهم استخدام أدنى جُرعة تسيطر على الألم لديك، ويجب عدم تناول هذا الدَّواء لوقت أطول من اللازم للسيطرة على الأعراض.اتصل بطبيبك في غضون أسبوعين من بدء العلاج إذا لم تشعر بأيِّ فائدة له.</p><p>الجُرعة المُوصى بها هي:</p><p dir="RTL"><strong>لعلاج داء المفاصل التنكسي (التهاب المفاصل)</strong></p><p dir="RTL">يُوصى بجرعة قدرها 200 مجم كل يوم، على أن يقوم طبيبك بزيادتها إلى 400 مجم بحد أقصى، إذا لزم الأمر.</p><p dir="RTL">تكون الجرعة عادة كالتَّالي:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كبسولة واحدة 200 مجم مرة واحدة يوميًّا؛ أو</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كبسولة واحدة 100 مجم مرتين يوميًّا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>لعلاج مرض التهاب المفاصل الروماتيزمي (التهاب المفاصل الروماتويدي)</strong></p><p dir="RTL">يُوصى بجرعة قدرها 200 مجم كل يوم، على أن يقوم طبيبك بزيادتها إلى 400 مجم كحد أقصى، إذا لزم الأمر.</p><p dir="RTL">تكون الجرعة عادة كالتَّالي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كبسولة واحدة 100 مجم مرتين يوميًّا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لعلاج بعض أنواع التهاب المفاصل بين الفقرات (التهاب الفقار اللاصق)</strong></p><p dir="RTL">يُوصى بجرعة قدرها 200 مجم كل يوم، على أن يقوم طبيبك بزيادتها إلى 400 مجم كحد أقصى، إذا لزم الأمر. تكون الجرعة عادة كالتَّالي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كبسولة واحدة 200 مجم مرة واحدة يوميًّا؛ أو</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كبسولة واحدة 100 مجم مرتين يوميًّا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>لا تتناول أكثر من 400 مجم في اليوم</strong> في جميع الاستخدامات العلاجية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كبار السن </strong></p><p dir="RTL">إذا كان عمرك يزيد على 65 عامًا ولا سيَّما إذا كان وزنك أقل من 50 كجم، فقد يرغب طبيبك في مراقبة حالتك بشكل أكثر دقة.</p><p>مشاكل الكُلى أو الكبد</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">تأكَّد من علم طبيبك إذا كنت تعاني من مشاكل في الكبد أو الكُلى أم لا؛ إذ قد تحتاج إلى جرعة أقل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة الاستخدام عقار ريفكوكس</strong></p><p dir="RTL">مُعد للاستخدام عن طريق الفم. تناوَل كبسولتك (كبسولاتك) على النحو التَّالي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع الكبسولة (الكبسولات) كاملة مع كوب من الماء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُفضل في نفس الوقت من كل يوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنك تناولها مع الطعام أو بدونه.</p><p dir="RTL">إذا كنت تواجه صعوبة في ابتلاع الكبسولات: يُمكِن نثر محتويات الكبسولة بالكامل على ملعقة صغيرة تحتوي على طعام شبه صلب (مثل: صوص التفاح البارد أو في درجة حرارة الغرفة أو عصيدة الأرز أو الزبادي أو الموز المهروس) وابتلعها فورًا مع كوب من الماء.</p><p dir="RTL">لفتح الكبسولة، أمسكها بوضعية قائمة لتكون الحبيبات بالجزء السفلي، ثم اضغط برفق على الجزء العلوي ولفه لنزعه، مع الحرص على عدم سقوط المحتويات. <strong>لا تقم بمضغ أو طحن الكريات.</strong></p><p dir="RTL"><strong>إذا تناولت كمية أكثر مما يجب من عقار ريفكوكس</strong></p><p dir="RTL">إذا تناولت كمية أكثر مما يجب من الكبسولات، فاتصل بأقرب مستشفى لك بها قسم طوارئ أو أخبر طبيبك فورًا. خذ معك دواءك لتُظهر للطبيب ما الذي تناولته.</p><p dir="RTL"><strong>إذا أغفلت تناوُل عقار ريفكوكس </strong></p><p dir="RTL">من المُهِم تناوُل دوائك كل يوم. مع ذلك، إذا أغفلت تناوُل جرعة أو أكثر، فتناولها بمجرد تذكرك لها وبعد ذلك استمر في تناول الجرعات بحسب جدولك المعتاد. لا تتناول جرعة مضاعفة لتعويض جرعة أغفلتها.</p><p dir="RTL"><strong>&nbsp;إذا توقفت عن تناول ريفكوكس</strong></p><p dir="RTL">استشر طبيبك دائمًا قبل أن تتوقف عن تناوُل هذا الدَّواء. حتى إذا شعرت بأنك على ما يُرام، قد يقرر طبيبك أنه من الضَّروري مواصلة تناوُل هذا الدَّواء.</p><p dir="RTL">&nbsp;إذا كانت لديك أية أسئلة إضافية حول استخدام هذا المنتج، فاستشر طبيبك أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">لا تستعمل هذا الدَّواء بعد تاريخ انتهاء الصلاحية المدون على العبوة والشريط بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&nbsp;قم بتخزينه في درجة حرارة أقل من 25 درجة مؤية. لا تتخلص من الأدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعد تستخدمها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ريفكوكس 100 مجم كبسولات، صلبة: المادة الفعالة هي سيليكوكسيب. تحتوي كل كبسولة صلبةعلى 100 مجم من سيليكوكسيب.</p><p dir="RTL">ريفكوكس 200 مجم كبسولات، صلبة: المادة الفعالة هي سيليكوكسيب. تحتوي كل كبسولة صلبةعلى 200 مجم من سيليكوكسيب.</p><p dir="RTL">المكونات الأخرى هي:</p><p dir="RTL">محتويات كبسولات عقار ريفكوكس100 مجم و 200 مجم كبسولات، صلبة: كاراجينان (E407)، لوريل سلفات الصوديوم، لاكتوز أحادي الهيدرات، سليلوز دقيق التَّبلور (E460)، ستيرات الماغنسيوم (E470b)، سيليكا غروية لا مائية (E551)، تلك (E553b).</p><p dir="RTL">غلاف كبسولات عقار ريفكوكس100 مجم كبسولات، صلبة: جيلاتين (E441)، ثاني أكسيد التيتانيوم (E171)، انديجو كارمين(E132).</p><p dir="RTL">غلاف كبسولات عقار ريفكوكس200 مجم كبسولات، صلبة:</p><p dir="RTL">جيلاتين (E441)، ثاني أكسيد التيتانيوم (E171)، أكسيد الحديد الأحمر (E172) أكسيد الحديد الأصفر (E172).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ريفكوكس 100 مجم كبسولات، صلبة:</p><p dir="RTL">للكبسولات (يبلغ طولها 17.7 &ndash; 18.3 مللي متر) جسم أبيض اللون وغطاء أزرق اللون، وتحتوي على حُبيبات بيضاء مائلة إلى اللون الأصفر الفاتح.</p><p dir="RTL">ريفكوكس 200 مجم كبسولات، صلبة:</p><p dir="RTL">للكبسولات (يبلغ طولها 19.1 &ndash; 19.7 مللي متر) جسم أبيض اللون وغطاء برتقالي اللون، وتحتوي على حُبيبات بيضاء مائلة إلى اللون الأصفر الفاتح.</p><p>يتم تعبئة كبسولات عقار ريفكوكس الصلبة في شرائط من بولي فينيل الكلوريد/التِّيلوريوم/بولي فينيليدين كلوريد/رقائق الألومنيوم. تحتوي العبوة على الآتي: 10، 20، 30، 50، 60، 90 أو 100 كبسولات صلبة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التَّسويق</strong></p><p dir="RTL">شركة ساندوز المحدودة</p><p dir="RTL">بيوكيميستراس 10</p><p dir="RTL">كوندل، النمسا</p><p dir="RTL"><strong>جهة التَّصنيع</strong></p><p dir="RTL">شركة ليك للصناعات الدَّوائية المساهمة،</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أبريل 2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Revcox 100 mg capsules, hard Revcox 200 mg capsules, hard
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Revcox 100 mg capsule, hard: Each hard capsule contains 100 mg celecoxib.
Excipient(s) with known effect: Each hard capsule contains 6.65 mg lactose (as lactose monohydrate).

Revcox 200 mg capsule, hard Each hard capsule contains 200 mg celecoxib.
Excipient(s) with known effect: Each hard capsule contains 13.3 mg lactose (as lactose monohydrate).

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Capsule, hard.

Revcox 100 mg capsules, hard:
Capsule (length 17.7 – 18.3 mm): white body and blue cap, containing white to slightly yellowish pellets.
Revcox 200	mg	capsules,	hard:  Capsule (length 19.1 – 19.7 mm): white body and orange cap, containing white to slightly yellowish pellets.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In adults for the symptomatic relief in the treatment of:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; osteoarthritis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rheumatoid arthritis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ankylosing spondylitis</p><p>&nbsp;</p><p>The decision to prescribe a selective cyclooxygenase-2 (COX-2) inhibitor should be based on an assessment of the individual patient&rsquo;s overall risks (see sections 4.3 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>As the cardiovascular risks of celecoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient&rsquo;s need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis (see sections 4.3, 4.4, 4.8 and 5.1).</p><p>&nbsp;</p><p><em>Osteoarthritis</em></p><p>The usual recommended daily dose is 200 mg taken once daily or in two divided doses. In some patients, with insufficient relief from symptoms, an increased dose of 200 mg twice daily may increase efficacy. In the absence of an increase in therapeutic benefit after two weeks, other therapeutic options should be considered.</p><p>&nbsp;</p><p><em>Rheumatoid arthritis</em></p><p>The initial recommended daily dose is 200 mg taken in two divided doses. The dose may, if needed, later be increased to 200 mg twice daily. In the absence of an increase in therapeutic benefit after two weeks, other therapeutic options should be considered.</p><p>&nbsp;</p><p><em>Ankylosing spondylitis</em></p><p>The recommended daily dose is 200 mg taken once daily or in two divided doses. In a few patients, with insufficient relief from symptoms, an increased dose of 400 mg once daily or in two divided doses may increase efficacy. In the absence of an increase in therapeutic benefit after two weeks, other therapeutic options should be considered.</p><p>The maximum recommended daily dose is 400 mg for all indications. <u>Special populations</u></p><p><em>Elderly (&gt;65 years)</em></p><p>As in younger adults, 200 mg per day should be used initially. The dose may, if needed, later be increased to 200 mg twice daily. Particular caution should be exercised in elderly with a body weight less than 50 kg (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Celecoxib is not indicated for use in children.</p><p>&nbsp;</p><p><em>CYP2C9 poor metabolisers</em></p><p>Patients who are known, or suspected to be CYP2C9 poor metabolisers based on genotyping or previous history/experience with other CYP2C9 substrates should be administered celecoxib with caution as the risk of dose-dependent adverse effects is increased. Consider reducing the dose to half the lowest recommended dose (see section 5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Treatment should be initiated at half the recommended dose in patients with established moderate liver</p><p>&nbsp;</p><p>impairment with a serum albumin of 25-35 g/l. Experience in such patients is limited to cirrhotic patients (see sections 4.3, 4.4 and 5.2).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>Experience with celecoxib in patients with mild or moderate renal impairment is limited, therefore such patients should be treated with caution (see sections 4.3, 4.4 and 5.2).</p><p>&nbsp;</p><p><u>Method of administration </u>Oral use</p><p>&nbsp;</p><p>Revcox may be taken with or without food.</p><p>&nbsp;</p><p>For patients who have difficulty swallowing capsules, the contents of a celecoxib capsule can be added to applesauce, rice gruel, yogurt or mashed banana. To do so, the entire capsule contents must be carefully emptied onto a level teaspoon of cool or room temperature applesauce, rice gruel, yogurt or mashed banana and should be ingested immediately with a glass of water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
-	Known hypersensitivity to sulfonamides.
-	Active peptic ulceration or gastrointestinal (GI) bleeding.
-	Patients who have experienced asthma, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria or other allergic-type reactions after taking acetylsalicylic acid or other non-steroidal anti- inflammatory drugs (NSAIDs) including cyclooxygenase-2 (COX-2) inhibitors.
-	In pregnancy and in women of childbearing potential unless using an effective method of contraception (see section 4.6). Celecoxib has been shown to cause malformations in the two animal species studied (see sections 4.6 and 5.3). The potential for human risk in pregnancy is unknown, but cannot be excluded.
-	Breast-feeding (see sections 4.6 and 5.3).
-	Severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score ≥10).
-	Patients with estimated creatinine clearance <30 ml/min.
-	Inflammatory bowel disease.
-	Congestive heart failure (NYHA II-IV).
-	Established ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Gastrointestinal (GI) effects</u></p><p>Upper and lower gastrointestinal complications (perforations, ulcers or bleedings [PUBs]), some of them resulting in fatal outcome, have occurred in patients treated with celecoxib. Caution is advised with treatment of patients most at risk of developing a gastrointestinal complication with NSAIDs; the elderly, patients using any other NSAID or antiplatelet medicinal products (such as acetylsalicylic acid) or glucocorticoids concomitantly, patients using alcohol, or patients with a prior history of gastrointestinal disease, such as ulceration and GI bleeding.</p><p>&nbsp;</p><p>There is further increase in the risk of gastrointestinal adverse effects for celecoxib (gastrointestinal ulceration or other gastrointestinal complications), when celecoxib is taken concomitantly with acetylsalicylic acid (even at low doses).</p><p>&nbsp;</p><p>A significant difference in GI safety between selective COX-2 inhibitors plus acetylsalicylic acid vs. NSAIDs plus acetylsalicylic acid has not been demonstrated in long-term clinical trials (see section 5.1).</p><p>&nbsp;</p><p><u>Concomitant NSAID use</u></p><p>The concomitant use of celecoxib and a non-acetylsalicylic acid NSAID should be avoided.</p><p>&nbsp;</p><p><u>Cardiovascular effects</u></p><p>Increased number of serious cardiovascular events, mainly myocardial infarction, has been found in a long-term placebo-controlled study in subjects with sporadic adenomatous polyps treated with celecoxib at doses of 200 mg twice daily and 400 mg twice daily compared to placebo (see section 5.1).</p><p>&nbsp;</p><p>As the cardiovascular risks of celecoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. NSAIDs, including COX-2 selective inhibitors, have been associated with increased risk of cardiovascular and thrombotic adverse events when taken long term. The exact magnitude of the risk associated with a single dose has not been determined, nor has the exact duration of therapy associated with increased risk. The patient&rsquo;s need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis (see sections 4.2, 4.3, 4.8 and 5.1).</p><p>&nbsp;</p><p>Patients with significant risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking) should only be treated with celecoxib after careful consideration (see section 5.1).</p><p>&nbsp;</p><p>COX-2 selective inhibitors are not a substitute for acetylsalicylic acid for prophylaxis of cardiovascular thrombo-embolic diseases because of their lack of antiplatelet effects. Therefore, antiplatelet therapies should not be discontinued (see section 5.1).</p><p>&nbsp;</p><p><u>Fluid retention and oedema</u></p><p>As with other active substances known to inhibit prostaglandin synthesis fluid retention and oedema have been observed in patients taking celecoxib. Therefore, celecoxib should be used with caution in</p><p>&nbsp;</p><p>patients with history of cardiac failure, left ventricular dysfunction or hypertension, and in patients with pre-existing oedema from any other reason, since prostaglandin inhibition may result in deterioration of renal function and fluid retention. Caution is also required in patients taking diuretic treatment or otherwise at risk of hypovolaemia.</p><p>&nbsp;</p><p><u>Hypertension</u></p><p>As with all NSAIDs, celecoxib can lead to the onset of new hypertension or worsening of pre- existing hypertension, either of which may contribute to the increased incidence of cardiovascular events. Therefore, blood pressure should be monitored closely during the initiation of therapy with celecoxib and throughout the course of therapy.</p><p>&nbsp;</p><p><u>Hepatic and renal effects</u></p><p>Compromised renal or hepatic function and especially cardiac dysfunction are more likely in the elderly and therefore medically appropriate supervision should be maintained.</p><p>&nbsp;</p><p>NSAIDs, including celecoxib, may cause renal toxicity. Clinical trials with celecoxib have shown renal effects similar to those observed with comparator NSAIDs. Patients at greatest risk for renal toxicity are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics, angiotensin converting enzyme (ACE)-inhibitors, angiotensin II receptor antagonists, and the elderly (see section 4.5). Such patients should be carefully monitored while receiving treatment with celecoxib.</p><p>&nbsp;</p><p>Some cases of severe hepatic reactions, including fulminant hepatitis (some with fatal outcome), liver necrosis and, hepatic failure (some with fatal outcome or requiring liver transplant), have been reported with celecoxib. Among the cases that reported time to onset, most of the severe adverse hepatic events developed within one month after initiation of celecoxib treatment (see section 4.8).</p><p>&nbsp;</p><p>If during treatment, patients deteriorate in any of the organ system functions described above, appropriate measures should be taken and discontinuation of celecoxib therapy should be considered.</p><p>&nbsp;</p><p><u>CYP2D6 inhibition</u></p><p>Celecoxib inhibits CYP2D6. Although it is not a strong inhibitor of this enzyme, a dose reduction may be necessary for individually dose-titrated medicinal products that are metabolised by CYP2D6 (see section 4.5).</p><p>&nbsp;</p><p><u>CYP2C9 poor metabolisers</u></p><p>Patients known to be CYP2C9 poor metabolisers should be treated with caution (see section 5.2).</p><p>&nbsp;</p><p><u>Skin and systemic hypersensitivity reactions</u></p><p>Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of celecoxib (see section 4.8). Patients appear to be at highest risk for these reactions early in the course of therapy: the onset of the reaction occurring in the majority of cases within the first month of treatment. Serious hypersensitivity reactions (including anaphylaxis, angioedema and drug rash with eosinophilia and systemic symptoms [DRESS, or hypersensitivity syndrome]) have been reported in patients receiving celecoxib (see section 4.8). Patients with a history of sulfonamide allergy or any medicinal product allergy may be at greater risk of serious skin reactions or hypersensitivity reactions (see section 4.3). Celecoxib should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.</p><p>&nbsp;</p><p><u>General</u></p><p>Celecoxib may mask fever and other signs of inflammation.</p><p>&nbsp;</p><p><u>Use with oral anticoagulants</u></p><p>In patients on concurrent therapy with warfarin, serious bleeding events, some of them fatal, have been reported. Increased prothrombin time (INR) with concurrent therapy has been reported.</p><p>Therefore, this should be closely monitored in patients receiving warfarin/coumarin-type oral anticoagulants, particularly when therapy with celecoxib is initiated or celecoxib dose is changed</p><p>&nbsp;</p><p>(see section 4.5). Concomitant use of anticoagulants with NSAIDs may increase the risk of bleeding. Caution should be exercised when combining celecoxib with warfarin or other oral anticoagulants, including novel anticoagulants (e.g. apixaban, dabigatran and rivaroxaban).</p><p>&nbsp;</p><p><u>Excipients</u></p><p>Revcox 100 mg and 200 mg capsules contain lactose (see section 2). Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p><p>&nbsp;</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antiinflammatory and antirheumatic products, Coxibs, ATC code: M01AH01</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Celecoxib is an oral, selective, cyclooxygenase-2 (COX-2) inhibitor within the clinical dose range (200-400 mg daily). No statistically significant inhibition of COX-1 (assessed as <em>ex vivo </em>inhibition of thromboxane B2 [TxB2] formation) was observed in this dose range in healthy volunteers.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>Cyclooxygenase is responsible for generation of prostaglandins. Two isoforms, COX-1 and COX-2, have been identified. COX-2 is the isoform of the enzyme that has been shown to be induced by pro- inflammatory stimuli and has been postulated to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever. COX-2 is also involved in ovulation, implantation and closure of the ductus arteriosus, regulation of renal function, and central nervous system functions (fever induction, pain perception and cognitive function). It may also play a role in ulcer healing. COX-2 has been identified in tissue around gastric ulcers in humans but its relevance to ulcer healing has not been established.</p><p>&nbsp;</p><p>The difference in antiplatelet activity between some COX-1 inhibiting NSAIDs and COX-2 selective inhibitors may be of clinical significance in patients at risk of thrombo-embolic reactions. COX-2 selective inhibitors reduce the formation of systemic (and therefore possibly endothelial) prostacyclin without affecting platelet thromboxane.</p><p>&nbsp;</p><p>Celecoxib is a diaryl-substituted pyrazole, chemically similar to other non-arylamine sulfonamides (e.g. thiazides, furosemide) but differs from arylamine sulfonamides (e.g. sulfamethoxazole and other sulfonamide antibiotics).</p><p>&nbsp;</p><p>A dose dependent effect on TxB2 formation has been observed after high doses of celecoxib. However, in healthy subjects, in small multiple dose studies with 600 mg twice daily (three times the</p><p>&nbsp;</p><p>highest recommended dose) celecoxib had no effect on platelet aggregation and bleeding time compared to placebo.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>Several clinical studies have been performed confirming efficacy and safety in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Celecoxib was evaluated for the treatment of the inflammation and pain of osteoarthritis of the knee and hip in approximately 4,200 patients in placebo and active controlled trials of up to 12 weeks duration. It was also evaluated for treatment of the inflammation and pain of rheumatoid arthritis in approximately 2,100 patients in placebo and active controlled trials of up to 24 weeks duration. Celecoxib at daily doses of 200 mg - 400 mg provided pain relief within 24 hours of dosing. Celecoxib was evaluated for the symptomatic treatment of ankylosing spondylitis in 896 patients in placebo and active controlled trials of up to 12 weeks duration. Celecoxib at doses of 100 mg twice daily, 200 mg once daily, 200 mg twice daily and 400 mg once daily in these studies demonstrated significant improvement in pain, global disease activity and function in ankylosing spondylitis.</p><p>&nbsp;</p><p>Five randomised double-blind controlled studies have been conducted including scheduled upper gastrointestinal endoscopy in approximately 4,500 patients free from initial ulceration (celecoxib doses from 50 mg - 400 mg twice daily). In twelve week endoscopy studies celecoxib (100 - 800 mg per day) was associated with a significantly lower risk of gastroduodenal ulcers compared with naproxen (1,000 mg per day) and ibuprofen (2,400 mg per day). The data were inconsistent in comparison with diclofenac (150 mg per day). In two of the 12-week studies the percentage of patients with endoscopic gastroduodenal ulceration was not significantly different between placebo and celecoxib 200 mg twice daily and 400 mg twice daily.</p><p>&nbsp;</p><p>In a prospective long-term safety outcome study (6 to 15 month duration, CLASS study),</p><p>5,800 osteoarthritis and 2, 200 rheumatoid arthritis patients received celecoxib 400 mg twice daily (4-fold and 2-fold the recommended osteoarthritis and rheumatoid arthritis doses, respectively), ibuprofen 800 mg three times daily or diclofenac 75 mg twice daily (both at therapeutic doses).</p><p>Twenty-two percent of enrolled patients took concomitant low-dose acetylsalicylic acid (&le;325 mg/day), primarily for cardiovascular prophylaxis. For the primary endpoint complicated ulcers (defined as gastrointestinal bleeding, perforation or obstruction) celecoxib was not significantly different than either ibuprofen or diclofenac individually. Also for the combined NSAID group there was no statistically significant difference for complicated ulcers (relative risk 0.77, 95 % CI 0.41- 1.46, based on entire study duration). For the combined endpoint, complicated and symptomatic ulcers, the incidence was significantly lower in the celecoxib group compared to the NSAID group, relative risk 0.66, 95% CI 0.45-0.97, but not between celecoxib and diclofenac. Those patients on celecoxib and concomitant low-dose acetylsalicylic acid experienced 4-fold higher rates of complicated ulcers as compared to those on celecoxib alone. The incidence of clinically significant decreases in haemoglobin (&gt;2 g/dl), confirmed by repeat testing, was significantly lower in patients on celecoxib compared to the NSAID group, relative risk 0.29, 95% CI 0.17- 0.48. The significantly lower incidence of this event with celecoxib was maintained with or without acetylsalicylic acid use.</p><p>&nbsp;</p><p>In a prospective randomised 24 week safety study in patients who were aged <u>&ge;</u>60 years or had a history of gastroduodenal ulcers (users of ASA excluded), the percentages of patients with decreases in haemoglobin (<u>&ge;</u>2 g/dl) and/or haematocrit (<u>&ge;</u>10%) of defined or presumed GI origin were lower in patients treated with celecoxib 200 mg twice daily (N=2,238) compared to patients treated with diclofenac sustained release 75 mg twice daily plus omeprazole 20 mg once daily (N=2,246) (0.2 % vs. 1.1 % for defined GI origin, p= 0.004; 0.4 % vs. 2.4 % for presumed GI origin, p = 0.0001). The rates of clinically manifest GI complications such as perforation, obstruction or haemorrhage were very low with no differences between the treatment groups (4-5 per group).</p><p>&nbsp;</p><p><em>Cardiovascular safety &ndash; long-term studies involving subjects with sporadic adenomatous polyps </em>Two studies involving subjects with sporadic adenomatous polyps were conducted with celecoxib i.e., the APC trial (Adenoma Prevention with Celecoxib) and the PreSAP trial (Prevention of Spontaneous Adenomatous Polyps). In the APC trial, there was a dose-related increase in the composite endpoint of cardiovascular death, myocardial infarction, or stroke (adjudicated) with</p><p>&nbsp;</p><p>celecoxib compared to placebo over 3 years of treatment. The PreSAP trial did not demonstrate a statistically significant increased risk for the same composite endpoint.</p><p>&nbsp;</p><p>In the APC trial, the relative risks compared to placebo for a composite endpoint (adjudicated) of cardiovascular death, myocardial infarction, or stroke were 3.4 (95% CI 1.4 - 8.5) with celecoxib 400 mg twice daily and 2.8 (95% CI 1.1- 7.2) with celecoxib 200 mg twice daily. Cumulative rates for this composite endpoint over 3 years were 3.0% (20/671 subjects) and 2.5% (17/685 subjects) respectively, compared to 0.9% (6/679 subjects) for placebo. The increases for both celecoxib dose groups versus placebo were mainly due to an increased incidence of myocardial infarction.</p><p>&nbsp;</p><p>In the PreSAP trial, the relative risk compared to placebo for this same composite endpoint (adjudicated) was 1.2 (95% CI 0.6 - 2.4) with celecoxib 400 mg once daily compared to placebo. Cumulative rates for this composite endpoint over 3 years were 2.3% (21/933 subjects) and 1.9% (12/628 subjects), respectively. The incidence of myocardial infarction (adjudicated) was 1.0% (9/933 subjects) with celecoxib 400 mg once daily and 0.6% (4/628 subjects) with placebo.</p><p>&nbsp;</p><p>Data from a third long-term study, ADAPT (The Alzheimer&rsquo;s Disease Anti-inflammatory Prevention Trial), did not show a significantly increased cardiovascular risk with celecoxib 200 mg twice daily compared to placebo. The relative risk compared to placebo for a similar composite endpoint (cardiovascular death, myocardial infarction, stroke) was 1.14 (95% CI 0.61 - 2.12) with celecoxib 200 mg twice daily. The incidence of myocardial infarction was 1.1% (8/717 patients) with celecoxib 200 mg twice daily and 1.2% (13/1070 patients) with placebo.</p><p>&nbsp;</p><p><em>Prospective Randomised Evaluation of Celecoxib Integrated Safety vs. Ibuprofen Or Naproxen (PRECISION)</em></p><p>The PRECISION study was a double-blind study of cardiovascular safety in OA or RA patients with or at high risk for cardiovascular disease comparing celecoxib (200-400 mg daily) with naproxen (750-1000 mg daily) and ibuprofen (1800-2400 mg daily). The primary endpoint, Antiplatelet Trialists Collaboration (APTC), was an independently adjudicated composite of cardiovascular death (including hemorrhagic death), non-fatal myocardial infarction or non-fatal stroke. The study was planned with 80% power to evaluate non-inferiority. All patients were prescribed open-label esomeprazole (20-40 mg) for gastro protection. Patients who were taking low-dose acetylsalicylic acid were permitted to continue therapy, at baseline nearly half of the subjects were on acetylsalicylic acid. Secondary and tertiary endpoints included cardiovascular, gastrointestinal and renal outcomes. The average dose dispensed was 209&plusmn;37 mg/day for celecoxib, 2045&plusmn;246 for ibuprofen and 852&plusmn;103 for naproxen<strong>.</strong></p><p><strong>&nbsp;</strong></p><p>Regarding the primary endpoint, celecoxib, as compared with either naproxen or ibuprofen, met all four pre-specified non-inferiority requirements, see Table 2.</p><p>&nbsp;</p><p>Other independently adjudicated secondary and tertiary endpoints included cardiovascular, gastrointestinal and renal outcomes. Additionally, there was a 4-month substudy focusing on the effects of the three active substances on blood pressure as measured by ambulatory monitoring (ABPM).</p><p>&nbsp;</p><p>Table 2. Primary analysis of the Adjudicated APTC Composite Endpoint</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Intent-To-Treat analysis (ITT, through month 30)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Celecoxib 100-200 mg bid</strong></p></td><td style="vertical-align:top"><p><strong>Ibuprofen 600-800 mg tid</strong></p></td><td style="vertical-align:top"><p><strong>Naproxen 375-500 mg bid</strong></p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>8,072</p></td><td style="vertical-align:top"><p>8,040</p></td><td style="vertical-align:top"><p>7,969</p></td></tr><tr><td style="vertical-align:top"><p>Subjects with events</p></td><td style="vertical-align:top"><p>188 (2.3%)</p></td><td style="vertical-align:top"><p>218 (2.7%)</p></td><td style="vertical-align:top"><p>201 (2.5%)</p></td></tr><tr><td style="vertical-align:top"><p>Pairwise comparison</p></td><td style="vertical-align:top"><p><strong>Celecoxib vs. naproxen</strong></p></td><td style="vertical-align:top"><p><strong>Celecoxib vs. ibuprofen</strong></p></td><td style="vertical-align:top"><p><strong>Ibuprofen vs. naproxen</strong></p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI)</p></td><td style="vertical-align:top"><p>0.93 (0.76, 1.13)</p></td><td style="vertical-align:top"><p>0.86 (0.70, 1.04)</p></td><td style="vertical-align:top"><p>1.08 (0.89, 1.31)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Modified Intent-To-Treat analysis (mITT, on treatment through month 43)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Celecoxib 100-200 mg bid</strong></p></td><td style="vertical-align:top"><p><strong>Ibuprofen 600-800 mg tid</strong></p></td><td style="vertical-align:top"><p><strong>Naproxen 375-500 mg bid</strong></p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>8,030</p></td><td style="vertical-align:top"><p>7,990</p></td><td style="vertical-align:top"><p>7,933</p></td></tr><tr><td style="vertical-align:top"><p>Subjects with events</p></td><td style="vertical-align:top"><p>134 (1.7%)</p></td><td style="vertical-align:top"><p>155 (1.9%)</p></td><td style="vertical-align:top"><p>144 (1.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Pairwise comparison</p></td><td style="vertical-align:top"><p><strong>Celecoxib vs. naproxen</strong></p></td><td style="vertical-align:top"><p><strong>Celecoxib vs. ibuprofen</strong></p></td><td style="vertical-align:top"><p><strong>Ibuprofen vs. naproxen</strong></p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI)</p></td><td style="vertical-align:top"><p>0.90 (0.72, 1.14)</p></td><td style="vertical-align:top"><p>0.81 (0.64, 1.02)</p></td><td style="vertical-align:top"><p>1.12 (0.889, 1.40)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>The results were overall numerically similar in the celecoxib and comparator groups for the secondary and tertiary endpoints and there were overall no unexpected safety findings.</p><p>&nbsp;</p><p>Taken together the PRECISION study indicates that celecoxib at the lowest approved dose of 100 mg twice daily is non-inferior to ibuprofen dosed in the range of 600 mg-800 mg three times daily or naproxen dosed in the range of 375 mg-500 mg twice daily with respect to cardiovascular adverse effects. The cardiovascular risks of the NSAID class, including coxibs, are dose-dependent, therefore, the results for celecoxib 200 mg daily on the composite cardiovascular endpoint cannot be extrapolated to dosing regimens using the higher doses of celecoxib.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Studies in animals (rats and rabbits) have shown reproductive toxicity, including malformations (see sections 4.3 and 5.3). Inhibition of prostaglandin synthesis might adversely affect pregnancy. Data from epidemiological studies suggest an increased risk of spontaneous abortion after use of prostaglandin synthesis inhibitors in early pregnancy. The potential for human risk in pregnancy is unknown, but cannot be excluded. Celecoxib, as with other active substances inhibiting prostaglandin synthesis, may cause uterine inertia and premature closure of the ductus arteriosus during the last trimester.</p><p>&nbsp;</p><p>During the second or third trimester of pregnancy, NSAIDs including celecoxib may cause fetal renal dysfunction which may result in reduction of amniotic fluid volume or oligohydramnios in severe cases. Such effects may occur shortly after treatment initiation and are usually reversible.</p><p>&nbsp;</p><p>Celecoxib is contraindicated in pregnancy and in women who can become pregnant (see section 4.3). If a woman becomes pregnant during treatment, celecoxib should be discontinued.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Celecoxib is excreted in the milk of lactating rats at concentrations similar to those in plasma. Administration of celecoxib to a limited number of lactating women has shown a very low transfer of celecoxib into breast milk. Celecoxib is contraindicated during breast-feeding (see section 4.3).</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Based on the mechanism of action, the use of NSAIDs, including celecoxib, may delay or prevent rupture of ovarian follicles, which has been associated with reversible infertility in some women.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients who experience dizziness, vertigo or somnolence while taking celecoxib should refrain from driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions are listed by system organ class and ranked by frequency in <strong>Table 1</strong>, reflecting data from the following sources:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions reported in osteoarthritis patients and rheumatoid arthritis patients at incidence rates greater than 0.01% and greater than those reported for placebo during</p><p>12 placebo- and/or active-controlled clinical trials of duration up to 12 weeks at celecoxib daily doses from 100 mg up to 800 mg. In additional studies using non-selective NSAID comparators, approximately 7400 arthritis patients have been treated with celecoxib at daily doses up to</p><p>800 mg, including approximately 2300 patients treated for 1 year or longer. The adverse reactions observed with celecoxib in these additional studies were consistent with those for osteoarthritis and rheumatoid arthritis patients listed in Table 1.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions reported at incidence rates greater than placebo for subjects treated with celecoxib 400 mg daily in long-term polyp prevention trials of duration up to 3 years (the Adenoma Prevention with Celecoxib (APC) and Prevention of Colorectal Sporadic Adenomatous Polyps (PreSAP) trials; see section 5.1 &ldquo;Cardiovascular safety &ndash; long-term studies involving patients with sporadic adenomatouspolyps&rdquo;).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse drug reactions from post-marketing surveillance as spontaneously reported during a period in which an estimated &gt;70 million patients were treated with celecoxib (various doses, durations, and indications). Even though these were identified as reactions from post-marketing reports, trial data were consulted to estimate frequency. Frequencies are based on a cumulative meta-analysis with pooling of trials representing exposure in 38,102 patients.</p><p>&nbsp;</p><p>Table 1. Adverse Drug Reactions in Celecoxib Clinical Trials and Surveillance Experience (MedDRA Preferred Terms)1,2</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System</strong></p></td><td style="vertical-align:top"><p><strong>Very</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>common</strong></p></td><td style="vertical-align:top"><p>(&ge;1/100 to</p></td><td style="vertical-align:top"><p>(&ge;1/1,000 to</p></td><td style="vertical-align:top"><p>(&ge;1/10,000 to</p></td><td style="vertical-align:top"><p>(&lt;1/10,000)</p></td><td style="vertical-align:top"><p><strong>not known</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(&ge;1/10)</p></td><td style="vertical-align:top"><p>&lt;1/10)</p></td><td style="vertical-align:top"><p>&lt;1/100)</p></td><td style="vertical-align:top"><p>&lt;1/1,000)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(cannot be</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>estimated</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>from the</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>available</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>data)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections</strong></p></td><td rowspan="9" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Sinusitis,</p></td><td rowspan="9" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="9" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="9" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="9" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>and</strong></p></td><td style="vertical-align:top"><p>upper</p></td></tr><tr><td style="vertical-align:top"><p><strong>infestations</strong></p></td><td style="vertical-align:top"><p>respiratory</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>tract</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>infection,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>pharyngitis</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>urinary</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>tract</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>infection</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic</strong></p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaemia</p></td><td style="vertical-align:top"><p>Leukopenia, thrombocyto-</p></td><td style="vertical-align:top"><p>Pancytopenia</p><p>4</p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>system</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>penia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system</strong></p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p>Hyper- sensitivity</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactic shock4,</p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>anaphylactic reaction4</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperkalaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>Anxiety, depression, fatigue</p></td><td style="vertical-align:top"><p>Confusional state, hallucinations4</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Very common </strong>(&ge;1/10)</p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p>(&ge;1/100 to</p><p>&lt;1/10)</p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p>(&ge;1/1,000 to</p><p>&lt;1/100)</p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p>(&ge;1/10,000 to</p><p>&lt;1/1,000)</p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p><p>(&lt;1/10,000)</p></td><td style="vertical-align:top"><p><strong>Frequency not known </strong>(cannot be estimated from the available data)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td rowspan="13" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dizziness, hypertonia, headache4</p></td><td style="vertical-align:top"><p>Cerebral infarction1, paraesthesia,</p></td><td style="vertical-align:top"><p>Ataxia, dysgeusia</p></td><td style="vertical-align:top"><p>Haemorrhage intracranial (including</p></td><td rowspan="13" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>somnolence</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>fatal</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>intracranial</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>haemorrhage</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>)4,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>meningitis</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>aseptic4,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>epilepsy</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(including</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>aggravated</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>epilepsy)4,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>ageusia4,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>anosmia4</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vision blurred, conjunctivitis4</p></td><td style="vertical-align:top"><p>Eye haemorrhage4</p></td><td style="vertical-align:top"><p>Retinal artery occlusion4,</p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>retinal vein</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>occlusion4</p></td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tinnitus, hypoacusis1</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myocardial infarction1</p></td><td style="vertical-align:top"><p>Cardiac failure, palpitations, tachycardia</p></td><td style="vertical-align:top"><p>Arrhythmia4</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>Hyper- tension1 (includin</p></td><td rowspan="6" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="6" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pulmonary embolism4, flushing4</p></td><td style="vertical-align:top"><p>Vasculitis4</p></td><td rowspan="6" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>g</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>aggravat</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>ed</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hyper-</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>tension)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Very common </strong>(&ge;1/10)</p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p>(&ge;1/100 to</p><p>&lt;1/10)</p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p>(&ge;1/1,000 to</p><p>&lt;1/100)</p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p>(&ge;1/10,000 to</p><p>&lt;1/1,000)</p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p><p>(&lt;1/10,000)</p></td><td style="vertical-align:top"><p><strong>Frequency not known </strong>(cannot be estimated from the available data)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory</strong></p><p><strong>, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rhinitis, cough, dyspnoea1</p></td><td style="vertical-align:top"><p>Bronchospasm4</p></td><td style="vertical-align:top"><p>Pneumonitis4</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastro-</strong></p></td><td rowspan="14" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Nausea4,</p></td><td style="vertical-align:top"><p>Constipation,</p></td><td style="vertical-align:top"><p>Gastro-</p></td><td rowspan="14" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="14" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>intestinal disorders</strong></p></td><td style="vertical-align:top"><p>abdominal pain,</p></td><td style="vertical-align:top"><p>gastritis, stomatitis,</p></td><td style="vertical-align:top"><p>intestinal haemorrhage4,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>diarrhoea,</p></td><td style="vertical-align:top"><p>gastrointestinal</p></td><td style="vertical-align:top"><p>duodenal</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>dyspepsia,</p></td><td style="vertical-align:top"><p>inflammation</p></td><td style="vertical-align:top"><p>ulcer,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>flatulence, vomiting1, dysphagia1</p></td><td style="vertical-align:top"><p>(including aggravation of gastrointestinal</p></td><td style="vertical-align:top"><p>gastric ulcer, oesophageal ulcer,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>inflammation),</p></td><td style="vertical-align:top"><p>intestinal and</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>eructation</p></td><td style="vertical-align:top"><p>large intestinal</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>ulcer,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>intestinal</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>perforation,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>oesophagitis,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>melaena,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>pancreatitis,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>colitis4</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Very common </strong>(&ge;1/10)</p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p>(&ge;1/100 to</p><p>&lt;1/10)</p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p>(&ge;1/1,000 to</p><p>&lt;1/100)</p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p>(&ge;1/10,000 to</p><p>&lt;1/1,000)</p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p><p>(&lt;1/10,000)</p></td><td style="vertical-align:top"><p><strong>Frequency not known </strong>(cannot be estimated from the available data)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepato- biliary</strong></p></td><td rowspan="17" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="17" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hepatic function abnormal,</p></td><td style="vertical-align:top"><p>Hepatitis4</p></td><td style="vertical-align:top"><p>Hepatic failure4</p></td><td rowspan="17" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>hepatic enzymes</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(sometimes</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>fatal or</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(including</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>requiring</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>increased SGOT</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>liver</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>and SGPT)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>transplant),</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hepatitis</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>fulminant4</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(some with</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>fatal</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>outcome),</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hepatic</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>necrosis4,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>cholestasis4,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hepatitis</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>cholestatic4,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>jaundice4</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Very common </strong>(&ge;1/10)</p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p>(&ge;1/100 to</p><p>&lt;1/10)</p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p>(&ge;1/1,000 to</p><p>&lt;1/100)</p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p>(&ge;1/10,000 to</p><p>&lt;1/1,000)</p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p><p>(&lt;1/10,000)</p></td><td style="vertical-align:top"><p><strong>Frequency not known </strong>(cannot be estimated from the available data)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcuta-</strong></p></td><td rowspan="21" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash, pruritus</p></td><td style="vertical-align:top"><p>Urticaria, ecchymosis4</p></td><td style="vertical-align:top"><p>Angioedema4,</p><p>alopecia,</p></td><td style="vertical-align:top"><p>Dermatitis exfoliative4,</p></td><td rowspan="21" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>neous tissue disorders</strong></p></td><td style="vertical-align:top"><p>(includes pruritus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>photosensi- tivity</p></td><td style="vertical-align:top"><p>erythema multiforme4,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>generalised)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Stevens-</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Johnson</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>syndrome4,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>toxic</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>epidermal</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>necrolysis4,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>drug reaction</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>with</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>eosinophilia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>and systemic</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>symptoms</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(DRESS)4,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>acute</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>generalised</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>exanthemato</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>us pustulosis</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(AGEP)4,</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>dermatitis</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>bullous4</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoske</strong></p></td><td rowspan="5" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arthralgia4</p></td><td style="vertical-align:top"><p>Muscle spasms</p></td><td rowspan="5" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myositis4</p></td><td rowspan="5" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>letal and</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(leg cramps)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>connective</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>tissue</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td rowspan="5" style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="5" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blood creatinine increased,</p><p>blood urea increased</p></td><td style="vertical-align:top"><p>Renal failure acute4,</p><p>hypo- natraemia4</p></td><td style="vertical-align:top"><p>Tubulointerst itial nephritis4, nephrotic syndrome4,</p></td><td rowspan="5" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>glomerulone</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>phritis</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>minimal</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>lesion4</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Very common </strong>(&ge;1/10)</p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p>(&ge;1/100 to</p><p>&lt;1/10)</p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p>(&ge;1/1,000 to</p><p>&lt;1/100)</p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p>(&ge;1/10,000 to</p><p>&lt;1/1,000)</p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p><p>(&lt;1/10,000)</p></td><td style="vertical-align:top"><p><strong>Frequency not known </strong>(cannot be estimated from the available data)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproduc- tive system and breast disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Menstrual disorder4</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Infertility female (female fertility decreased)3</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administra- tion site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Influenza- like illness, oedema peripheral/f luid retention</p></td><td style="vertical-align:top"><p>Face oedema, chest pain4</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Injury, poisoning and procedural complicatio ns</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Injury (accidental injury)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="6" style="vertical-align:top"><p>1 Adverse drug reactions that occurred in polyp prevention trials, representing subjects</p><p>treated with celecoxib 400 mg daily in 2 clinical trials of duration up to 3 years (the APC and PreSAP trials). The adverse drug reactions listed above for the polyp prevention trials are only those that have been previously recognized in the post- marketing surveillance experience, or have occurred more frequently than in the arthritis trials.</p><p>2 Furthermore, the following <em>previously unknown </em>adverse reactions occurred in polyp prevention trials, representing subjects treated with celecoxib 400 mg daily in 2 clinical trials of duration up to 3 years (the APC and PreSAP trials):</p><p><strong>Common: </strong>angina pectoris, irritable bowel syndrome, nephrolithiasis, blood creatinine increased, benign prostatic hyperplasia, weight increased. <strong>Uncommon: </strong>helicobacter infection, herpes zoster, erysipelas, bronchopneumonia, labyrinthitis, gingival infection, lipoma, vitreous floaters, conjunctival haemorrhage, deep vein thrombosis, dysphonia, haemorrhoidal haemorrhage, frequent bowel movements, mouth ulceration, allergic dermatitis, ganglion, nocturia, vaginal haemorrhage, breast tenderness, lower limb fracture, blood sodium increased.</p><p>3 Women intending to become pregnant are excluded from all trials, thus consultation of the trial database for the frequency of this event was not reasonable.</p><p>4 Frequencies are based on cumulative meta-analysis with pooling of trials representing</p><p>exposure in 38,102 patients.</p></td></tr></tbody></table><p>&nbsp;</p><p>In final data (adjudicated) from the APC and PreSAP trials in patients treated with celecoxib 400 mg daily for up to 3 years (pooled data from both trials; see section 5.1 for results from individual trials), the excess rate over placebo for myocardial infarction was 7.6 events per 1,000 patients (uncommon) and there was no excess rate for stroke (types not differentiated) over placebo.</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p>&nbsp;<!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt;letter-spacing:-2.45pt'><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='width:454.6pt;
 height:68.65pt;mso-left-percent:-10001;mso-top-percent:-10001;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:char;
 mso-position-vertical:absolute;mso-position-vertical-relative:line;
 mso-left-percent:-10001;mso-top-percent:-10001' filled="f" strokeweight=".48pt">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoListParagraph style='margin-left:11.55pt;text-indent:-6.4pt;
    line-height:12.3pt;mso-line-height-rule:exactly;mso-list:l1 level1 lfo2;
    tab-stops:11.6pt'><![if !supportLists]><span style='mso-font-width:99%'><span
    style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
    dir=LTR></span>National Pharmacovigilance Center<span style='letter-spacing:
    -1.0pt'> </span>(NPC):<o:p></o:p></p>
    <p class=MsoListParagraph style='margin-left:33.5pt;text-indent:-10.35pt;
    line-height:12.95pt;mso-line-height-rule:exactly;mso-list:l1 level2 lfo2;
    tab-stops:33.55pt'><![if !supportLists]><span style='font-family:Symbol;
    mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-font-width:
    99%'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span>Toll free phone:<span
    style='letter-spacing:-.6pt'> </span>8002490000<o:p></o:p></p>
    <p class=MsoBodyText style='margin-left:23.1pt;line-height:13.0pt;
    mso-line-height-rule:exactly'><span style='font-family:Symbol'>·</span><span
    style='mso-spacerun:yes'>  </span>Fax: +966-11-205-7662<o:p></o:p></p>
    <p class=MsoListParagraph style='margin-left:33.5pt;text-indent:-10.35pt;
    line-height:13.0pt;mso-line-height-rule:exactly;mso-list:l1 level2 lfo2;
    tab-stops:33.55pt'><![if !supportLists]><span style='font-family:Symbol;
    mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-font-width:
    99%'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span>E-mail:<span
    style='letter-spacing:2.15pt'> </span><a href="mailto:npc.drug@sfda.gov.sa"><span
    style='color:windowtext;text-decoration:none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
    <p class=MsoListParagraph style='margin-left:33.5pt;text-indent:-10.35pt;
    line-height:13.25pt;mso-line-height-rule:exactly;mso-list:l1 level2 lfo2;
    tab-stops:33.55pt'><![if !supportLists]><span style='font-family:Symbol;
    mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;mso-font-width:
    99%'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span>Website:<span
    style='letter-spacing:-.8pt'> </span><a href="http://www.ade.sfda.gov.sa/"><span
    style='color:windowtext;text-decoration:none;text-underline:none'>www.ade.sfda.gov.sa</span></a><o:p></o:p></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="612" height="98" alt="Text Box: -	National Pharmacovigilance Center (NPC):
•	Toll free phone: 8002490000
•  Fax: +966-11-205-7662
•	E-mail: npc.drug@sfda.gov.sa
•	Website: www.ade.sfda.gov.sa
" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:11.0pt;letter-spacing:-2.45pt'><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:454.6pt;height:68.65pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>&nbsp;</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:group
 id="_x0000_s1027" style='position:absolute;left:0;text-align:left;
 margin-left:54.35pt;margin-top:16.95pt;width:455.1pt;height:16.8pt;z-index:-59488;
 mso-position-horizontal-relative:page' coordorigin="1087,339" coordsize="9102,336">
 <v:line id="_x0000_s1028" style='position:absolute' from="1097,349" to="10178,349"
  strokeweight=".16969mm"/>
 <v:line id="_x0000_s1029" style='position:absolute' from="1092,344" to="1092,670"
  strokeweight=".48pt"/>
 <v:shape id="_x0000_s1030" style='position:absolute;left:1097;top:344;width:9087;
  height:326' coordorigin="1097,344" coordsize="9087,326" o:spt="100" adj="0,,0"
  path="m1097,665r9081,m10183,344r,326e" filled="f" strokeweight=".48pt">
  <v:stroke joinstyle="round"/>
  <v:formulas/>
  <v:path arrowok="t" o:connecttype="segments"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="608" height="24" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image002.gif" />Other GCC states:</p><p><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no clinical experience of overdose. Single doses up to 1,200 mg and multiple doses up to 1,200 mg twice daily have been administered to healthy subjects for nine days without clinically significant adverse effects. In the event of suspected overdose, appropriate supportive medical care should be provided e.g. by eliminating the gastric contents, clinical supervision and, if necessary, the institution of symptomatic treatment. Dialysis is unlikely to be an efficient method of active substance removal due to high protein binding.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antiinflammatory and antirheumatic products, Coxibs, ATC code: M01AH01</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Celecoxib is an oral, selective, cyclooxygenase-2 (COX-2) inhibitor within the clinical dose range (200-400 mg daily). No statistically significant inhibition of COX-1 (assessed as <em>ex vivo </em>inhibition of thromboxane B2 [TxB2] formation) was observed in this dose range in healthy volunteers.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>Cyclooxygenase is responsible for generation of prostaglandins. Two isoforms, COX-1 and COX-2, have been identified. COX-2 is the isoform of the enzyme that has been shown to be induced by pro- inflammatory stimuli and has been postulated to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever. COX-2 is also involved in ovulation, implantation and closure of the ductus arteriosus, regulation of renal function, and central nervous system functions (fever induction, pain perception and cognitive function). It may also play a role in ulcer healing. COX-2 has been identified in tissue around gastric ulcers in humans but its relevance to ulcer healing has not been established.</p><p>&nbsp;</p><p>The difference in antiplatelet activity between some COX-1 inhibiting NSAIDs and COX-2 selective inhibitors may be of clinical significance in patients at risk of thrombo-embolic reactions. COX-2</p><p>&nbsp;</p><p>selective inhibitors reduce the formation of systemic (and therefore possibly endothelial) prostacyclin without affecting platelet thromboxane.</p><p>&nbsp;</p><p>Celecoxib is a diaryl-substituted pyrazole, chemically similar to other non-arylamine sulfonamides (e.g. thiazides, furosemide) but differs from arylamine sulfonamides (e.g. sulfamethoxazole and other sulfonamide antibiotics).</p><p>&nbsp;</p><p>A dose dependent effect on TxB2 formation has been observed after high doses of celecoxib. However, in healthy subjects, in small multiple dose studies with 600 mg twice daily (three times the highest recommended dose) celecoxib had no effect on platelet aggregation and bleeding time compared to placebo.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>Several clinical studies have been performed confirming efficacy and safety in osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Celecoxib was evaluated for the treatment of the inflammation and pain of osteoarthritis of the knee and hip in approximately 4,200 patients in placebo and active controlled trials of up to 12 weeks duration. It was also evaluated for treatment of the inflammation and pain of rheumatoid arthritis in approximately 2,100 patients in placebo and active controlled trials of up to 24 weeks duration. Celecoxib at daily doses of 200 mg - 400 mg provided pain relief within 24 hours of dosing. Celecoxib was evaluated for the symptomatic treatment of ankylosing spondylitis in 896 patients in placebo and active controlled trials of up to 12 weeks duration. Celecoxib at doses of 100 mg twice daily, 200 mg once daily, 200 mg twice daily and</p><p>400 mg once daily in these studies demonstrated significant improvement in pain, global disease activity and function in ankylosing spondylitis.</p><p>&nbsp;</p><p>Five randomised double-blind controlled studies have been conducted including scheduled upper gastrointestinal endoscopy in approximately 4,500 patients free from initial ulceration (celecoxib doses from 50 mg - 400 mg twice daily). In twelve week endoscopy studies celecoxib (100 - 800 mg per day) was associated with a significantly lower risk of gastroduodenal ulcers compared with naproxen (1,000 mg per day) and ibuprofen (2,400 mg per day). The data were inconsistent in comparison with diclofenac (150 mg per day). In two of the 12-week studies the percentage of patients with endoscopic gastroduodenal ulceration was not significantly different between placebo and celecoxib 200 mg twice daily and 400 mg twice daily.</p><p>&nbsp;</p><p>In a prospective long-term safety outcome study (6 to 15 month duration, CLASS study),</p><p>5,800 osteoarthritis and 2, 200 rheumatoid arthritis patients received celecoxib 400 mg twice daily (4- fold and 2-fold the recommended osteoarthritis and rheumatoid arthritis doses, respectively), ibuprofen 800 mg three times daily or diclofenac 75 mg twice daily (both at therapeutic doses).</p><p>Twenty-two percent of enrolled patients took concomitant low-dose acetylsalicylic acid (&le;325 mg/day), primarily for cardiovascular prophylaxis. For the primary endpoint complicated ulcers (defined as gastrointestinal bleeding, perforation or obstruction) celecoxib was not significantly different than either ibuprofen or diclofenac individually. Also for the combined NSAID group there was no statistically significant difference for complicated ulcers (relative risk 0.77, 95 % CI 0.41-1.46, based on entire study duration). For the combined endpoint, complicated and symptomatic ulcers, the incidence was significantly lower in the celecoxib group compared to the NSAID group, relative risk</p><p>&nbsp;</p><p>0.66, 95% CI 0.45-0.97, but not between celecoxib and diclofenac. Those patients on celecoxib and concomitant low-dose acetylsalicylic acid experienced 4-fold higher rates of complicated ulcers as compared to those on celecoxib alone. The incidence of clinically significant decreases in haemoglobin (&gt;2 g/dl), confirmed by repeat testing, was significantly lower in patients on celecoxib compared to the NSAID group, relative risk 0.29, 95% CI 0.17- 0.48. The significantly lower incidence of this event with celecoxib was maintained with or without acetylsalicylic acid use.</p><p>&nbsp;</p><p>In a prospective randomised 24 week safety study in patients who were aged <u>&ge;</u>60 years or had a history of gastroduodenal ulcers (users of ASA excluded), the percentages of patients with decreases in haemoglobin (<u>&ge;</u>2 g/dl) and/or haematocrit (<u>&ge;</u>10%) of defined or presumed GI origin were lower in patients treated with celecoxib 200 mg twice daily (N=2,238) compared to patients treated with diclofenac sustained release 75 mg twice daily plus omeprazole 20 mg once daily (N=2,246) (0.2 % vs. 1.1 % for defined GI origin, p= 0.004; 0.4 % vs. 2.4 % for presumed GI origin, p = 0.0001). The rates of clinically manifest GI complications such as perforation, obstruction or haemorrhage were very low with no differences between the treatment groups (4-5 per group).</p><p>&nbsp;</p><p><em>Cardiovascular safety &ndash; long-term studies involving subjects with sporadic adenomatous polyps</em></p><p>Two studies involving subjects with sporadic adenomatous polyps were conducted with celecoxib i.e., the APC trial (Adenoma Prevention with Celecoxib) and the PreSAP trial (Prevention of Spontaneous Adenomatous Polyps). In the APC trial, there was a dose-related increase in the composite endpoint of cardiovascular death, myocardial infarction, or stroke (adjudicated) with celecoxib compared to placebo over 3 years of treatment. The PreSAP trial did not demonstrate a statistically significant increased risk for the same composite endpoint.</p><p>&nbsp;</p><p>In the APC trial, the relative risks compared to placebo for a composite endpoint (adjudicated) of cardiovascular death, myocardial infarction, or stroke were 3.4 (95% CI 1.4 - 8.5) with celecoxib</p><p>400 mg twice daily and 2.8 (95% CI 1.1- 7.2) with celecoxib 200 mg twice daily. Cumulative rates for this composite endpoint over 3 years were 3.0% (20/671 subjects) and 2.5% (17/685 subjects) respectively, compared to 0.9% (6/679 subjects) for placebo. The increases for both celecoxib dose groups versus placebo were mainly due to an increased incidence of myocardial infarction.</p><p>&nbsp;</p><p>In the PreSAP trial, the relative risk compared to placebo for this same composite endpoint (adjudicated) was 1.2 (95% CI 0.6 - 2.4) with celecoxib 400 mg once daily compared to placebo. Cumulative rates for this composite endpoint over 3 years were 2.3% (21/933 subjects) and 1.9% (12/628 subjects), respectively. The incidence of myocardial infarction (adjudicated) was 1.0% (9/933 subjects) with celecoxib 400 mg once daily and 0.6% (4/628 subjects) with placebo.</p><p>&nbsp;</p><p>Data from a third long-term study, ADAPT (The Alzheimer&rsquo;s Disease Anti-inflammatory Prevention Trial), did not show a significantly increased cardiovascular risk with celecoxib 200 mg twice daily compared to placebo. The relative risk compared to placebo for a similar composite endpoint (cardiovascular death, myocardial infarction, stroke) was 1.14 (95% CI 0.61 - 2.12) with celecoxib 200 mg twice daily. The incidence of myocardial infarction was 1.1% (8/717 patients) with celecoxib 200 mg twice daily and 1.2% (13/1070 patients) with placebo.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Celecoxib is well absorbed reaching peak plasma concentrations after approximately 2-3 hours. Dosing with food (high fat meal) delays absorption of celecoxib by about 1 hour resulting in a Tmax of about 4 hours and increases bioavailability by about 20%.</p><p>&nbsp;</p><p>In healthy adult volunteers, the overall systemic exposure (AUC) of celecoxib was equivalent when celecoxib was administered as intact capsule or capsule contents sprinkled on applesauce. There were no significant alterations in Cmax, Tmax or T1/2 after administration of capsule contents on applesauce.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Plasma protein binding is about 97% at therapeutic plasma concentrations and the active substance is not preferentially bound to erythrocytes.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Celecoxib metabolism is primarily mediated via cytochrome P450 2C9. Three metabolites, inactive as COX-1 or COX-2 inhibitors, have been identified in human plasma i.e., a primary alcohol, the corresponding carboxylic acid and its glucuronide conjugate.</p><p>&nbsp;</p><p>Cytochrome P450 2C9 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity, such as those homozygous for the CYP2C9*3 polymorphism.</p><p>In a pharmacokinetic study of celecoxib 200 mg administered once daily in healthy volunteers, genotyped as either CYP2C9*1/*1, CYP2C9*1/*3 or CYP2C9*3/*3, the median Cmax and AUC0-24 of celecoxib on day 7 were approximately 4-fold and 7-fold, respectively, in subjects, genotyped as CYP2C9*3/*3 compared to other genotypes. In three separate single dose studies, involving a total of 5 subjects genotyped as CYP2C9*3/*3, single-dose AUC0-24 increased by approximately 3-fold compared to normal metabolisers. It is estimated that the frequency of the homozygous *3/*3 genotype is 0.3%-1.0% among different ethnic groups. Patients who are known or suspected to be CYP2C9 poor metabolisers based on previous history/experience with other CYP2C9 substrates should be administered celecoxib with caution (see section 4.2).</p><p>&nbsp;</p><p>No clinically significant differences were found in PK parameters of celecoxib between elderly African-Americans and Caucasians.</p><p>&nbsp;</p><p>The plasma concentration of celecoxib is approximately 100% increased in elderly women (&gt;65 years).</p><p>&nbsp;</p><p>Compared to subjects with normal hepatic function, patients with mild hepatic impairment had a mean increase in Cmax of 53% and in AUC of 26% of celecoxib. The corresponding values in patients with moderate hepatic impairment were 41% and 146%, respectively. The metabolic capacity in patients with mild to moderate impairment was best correlated to their albumin values. Treatment should be initiated at half the recommended dose in patients with moderate liver impairment (with serum albumin 25-35 g/l). Patients with severe hepatic impairment (serum albumin &lt;25 g/l) have not been studied and celecoxib is contraindicated in this patient group.</p><p>&nbsp;</p><p>There is little experience of celecoxib in renal impairment. The pharmacokinetics of celecoxib has not been studied in patients with renal impairment but is unlikely to be markedly changed in these patients. Thus caution is advised when treating patients with renal impairment. Use of celecoxib in patients with severe renal impairment is contraindicated.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Celecoxib is mainly eliminated by metabolism. Less than 1% of the dose is excreted unchanged in urine. The inter-subject variability in the exposure of celecoxib is about 10-fold. Celecoxib exhibits dose- and time-independent pharmacokinetics in the therapeutic dose range. Elimination half-life is 8- 12 hours. Steady state plasma concentrations are reached within 5 days of treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical safety data revealed no special hazard for humans based on conventional studies of repeated dose toxicity, mutagenicity or carcinogenicity beyond those addressed in section 4.4, 4.6 and</p><p>5.1 of the SmPC.</p><p>&nbsp;</p><p>Celecoxib at oral doses &sup3;150 mg/kg/day (approximately 2-fold human exposure at 200 mg twice daily as measured by AUC0-24), caused an increased incidence of ventricular septal defects, a rare event, and fetal alterations, such as ribs fused, sternebrae fused and sternebrae misshapen when rabbits were treated throughout organogenesis. A dose-dependent increase in diaphragmatic hernias was observed when rats were given celecoxib at oral doses &sup3;30 mg/kg/day (approximately 6-fold human exposure based on the AUC0-24 at 200 mg twice daily) throughout organogenesis. These effects are expected following inhibition of prostaglandin synthesis. In rats, exposure to celecoxib during early embryonic development resulted in pre-implantation and post-implantation losses, and reduced embryo/fetal survival.</p><p>&nbsp;</p><p>Celecoxib was excreted in rat milk. In a peri-post natal study in rats, pup toxicity was observed.</p><p>In a 2-year toxicity study an increase in nonadrenal thrombosis was observed in male rat at high doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Capsules, content: </u>Carrageenan (E407), Sodium laurilsulphate, Lactose monohydrate,</p><p>Microcrystalline cellulose (E460), Magnesium stearate (E470b), Silica, colloidal, anhydrous (E551), Talc (E553b).</p><p>&nbsp;</p><p><u>Capsule shell:</u></p><p><em>body:</em></p><p>Gelatin (E441),</p><p>Titanium dioxide (E171).</p><p>&nbsp;</p><p>cap Revcox 100 mg capsules, hard: Gelatin (E441),</p><p>Titanium dioxide (E171), Indigo carmine (E132).</p><p>cap Revcox 200 mg capsules, hard: Gelatin (E441),</p><p>Titanium dioxide (E171), Iron oxide, red (E172), Iron oxide, yellow (E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>PVC/TE/PVDC/Alu foil blister containing 10 hard capsules. Pack sizes: 10, 20, 30, 50, 60, 90 or 100 hard capsules</p><p>Not all pack sizes may be marketed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sandoz GmbH Biochemiestrasse 10
Kundl, Austria

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>